CU20200086A7 - Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes - Google Patents

Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes

Info

Publication number
CU20200086A7
CU20200086A7 CU2020000086A CU20200086A CU20200086A7 CU 20200086 A7 CU20200086 A7 CU 20200086A7 CU 2020000086 A CU2020000086 A CU 2020000086A CU 20200086 A CU20200086 A CU 20200086A CU 20200086 A7 CU20200086 A7 CU 20200086A7
Authority
CU
Cuba
Prior art keywords
drug
activity against
antimicrobial activity
resistant pathogens
against multi
Prior art date
Application number
CU2020000086A
Other languages
English (en)
Other versions
CU24750B1 (es
Inventor
Perez Hilda Elisa Garay
Vivian Montero-Alejo
Rolando Perdomo-Morales
González Amanda Vázquez
Original Assignee
Centro De Investig Y Desarrollo De Medicamentos Cidem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investig Y Desarrollo De Medicamentos Cidem filed Critical Centro De Investig Y Desarrollo De Medicamentos Cidem
Priority to CU2020000086A priority Critical patent/CU24750B1/es
Priority to MX2023005925A priority patent/MX2023005925A/es
Priority to PCT/CU2021/050011 priority patent/WO2022105948A2/es
Priority to US18/037,534 priority patent/US20240239849A1/en
Priority to JP2023523524A priority patent/JP2024508205A/ja
Priority to CN202180071094.XA priority patent/CN116406282A/zh
Priority to CA3199519A priority patent/CA3199519A1/en
Priority to EP21865361.6A priority patent/EP4249500A2/en
Publication of CU20200086A7 publication Critical patent/CU20200086A7/es
Priority to CONC2023/0007878A priority patent/CO2023007878A2/es
Publication of CU24750B1 publication Critical patent/CU24750B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Insects & Arthropods (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>La presente invención describe compuestos peptídicos sintéticos que combaten microorganismos patógenos de naturaleza bacteriana, y que presentan como microorganismos multirresistentes a antibióticos convencionales. Además, describe terapias de combinación que contienen dichos péptidos. Se describen composiciones farmacéuticas que comprenden a los compuestos peptídicos y sus combinaciones.</p>
CU2020000086A 2020-11-19 2020-11-19 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes CU24750B1 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CU2020000086A CU24750B1 (es) 2020-11-19 2020-11-19 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes
MX2023005925A MX2023005925A (es) 2020-11-19 2021-11-18 Entidades peptidicas con actividad antimicrobiana frente a patogenos multi-drogoresistentes.
PCT/CU2021/050011 WO2022105948A2 (es) 2020-11-19 2021-11-18 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes
US18/037,534 US20240239849A1 (en) 2020-11-19 2021-11-18 Peptide entities with antimicrobial activity against multi-drug resistant pathogens
JP2023523524A JP2024508205A (ja) 2020-11-19 2021-11-18 多剤耐性病原体に対する抗菌活性を有するペプチド実体
CN202180071094.XA CN116406282A (zh) 2020-11-19 2021-11-18 具有针对多药耐药性病原体的抗微生物活性的肽实体
CA3199519A CA3199519A1 (en) 2020-11-19 2021-11-18 Peptide entities with antimicrobial activity against multi-drug resistant pathogens
EP21865361.6A EP4249500A2 (en) 2020-11-19 2021-11-18 Peptide entities with antimicrobial activity against multi-drug resistant pathogens
CONC2023/0007878A CO2023007878A2 (es) 2020-11-19 2023-06-15 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000086A CU24750B1 (es) 2020-11-19 2020-11-19 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes

Publications (2)

Publication Number Publication Date
CU20200086A7 true CU20200086A7 (es) 2022-06-06
CU24750B1 CU24750B1 (es) 2025-06-11

Family

ID=80684162

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000086A CU24750B1 (es) 2020-11-19 2020-11-19 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes

Country Status (9)

Country Link
US (1) US20240239849A1 (es)
EP (1) EP4249500A2 (es)
JP (1) JP2024508205A (es)
CN (1) CN116406282A (es)
CA (1) CA3199519A1 (es)
CO (1) CO2023007878A2 (es)
CU (1) CU24750B1 (es)
MX (1) MX2023005925A (es)
WO (1) WO2022105948A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117756904B (zh) * 2023-12-22 2024-05-24 潍坊医学院 一种订书肽及其应用
CN118666967B (zh) * 2024-03-06 2025-03-28 广东医保药业有限公司 多肽及其与头孢噻肟舒巴坦的组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637731D1 (de) * 1995-08-23 2008-12-11 Univ British Columbia Antimikrobielle kationische peptide und methoden zu ihrer identifizierung
CU24073B1 (es) 2011-12-27 2015-01-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem COMPOSICIÓN A PARTIR DE EXTRACTO DE HEMOCITOS DE LANGOSTA PARA LA DETECCIÓN DE LIPOPOLISACÁRIDOS, PEPTIDOGLICANOS Y 1,3-ß-D-GLUCANOS
CA3062852A1 (en) * 2017-05-11 2018-11-15 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Antimicrobial peptides with alpha-core helices
EP3946609A4 (en) * 2019-04-05 2023-05-03 Contrafect Corporation LYSINE AND ITS DERIVATIVES WITH BACTERICIDAL ACTIVITY AGAINST PSEUDOMONAS AERUGINOSA IN THE PRESENCE OF HUMAN SERUM

Also Published As

Publication number Publication date
CA3199519A1 (en) 2022-05-27
CN116406282A (zh) 2023-07-07
WO2022105948A3 (es) 2022-10-20
MX2023005925A (es) 2023-05-29
WO2022105948A2 (es) 2022-05-27
US20240239849A1 (en) 2024-07-18
EP4249500A2 (en) 2023-09-27
CO2023007878A2 (es) 2023-07-21
JP2024508205A (ja) 2024-02-26
CU24750B1 (es) 2025-06-11

Similar Documents

Publication Publication Date Title
MX2023007852A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
BR112017028413A2 (pt) peptídeos antimicrobianos estabilizados
EA202192738A1 (ru) Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
BR112018005114A2 (pt) um novo polipeptídeo de endolisina
MX2018015522A (es) Tratamiento de infeccion por clostridium difficile.
CO2018010459A2 (es) Composiciones que comprenden cepas bacterianas
CO2018011701A2 (es) Formulaciones de antibióticos glicopeptídicos estabilizados
AR119025A1 (es) Composición que comprende un bacillus formador de biopelícula
MX364942B (es) Peptidos antimicrobianos.
CU20200086A7 (es) Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
CL2017002482A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
EP3725321A4 (en) COMPOSITION WITH A BACTERIUM OF THE GENUS BIFIDOBACTERIUM AS THE ACTIVE SUBSTANCE
MX2021015961A (es) Moleculas novedosas.
MX2017012073A (es) Compuestos de minociclina para biodefensas.
WO2019077634A3 (en) Therapeutic compositions of antimicrobial peptides
BR112022000041A2 (pt) Inibidores de detecção de quorum e / ou metabólitos pósbióticos e métodos relacionados
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
CO2022009260A2 (es) Composiciones farmacéuticas oftálmicas
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
BR112021022902A2 (pt) Métodos e composições que compreendem variantes de proteína a staphylococcus (spa)
MX2018012671A (es) Combinacion, usos terapeuticos y usos profilacticos.
MX2021014310A (es) Formulaciones de terlipressina.
BR112013008037A2 (pt) compostos multivalentes como tratamento antibiótico
MX2023012704A (es) Cepas bacterianas que tienen actividad fungicida, composiciones que las comprenden y uso de estas.